Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Publisher: La Merie Publishing
Pages: 72
Format: PDF
Product Line:
Target Pipeline
Product Line:
Competitor Analysis
Product Code: LMCA0171
Release Date: June of 2018

400.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

This Competitive Intelligence report analyzes the competitive field of NY-ESO-1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

The New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a human tumor antigen of the cancer/testis family (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.

Cancer testis antigens are a unique class of tumor-associated antigens, because they are normally expressed in the adult male germ line, but not in other normal tissues, and are overexpressed in various malignancies. NY-ESO-1 being the most immunogenic among the cancer testis antigen family members. NY-ESO-1 spontaneously elicits humoral and cellular responses in many patients with cancer. Therefore, among tumor-associated antigens, it is one of the most promising antigens for immunotherapy, and different vaccines using NY-ESO-1 peptides, full-length NY-ESO-1 protein, or NY-ESO-1 DNA are being evaluated in clinical trials.

Transfer of T-cell receptors (TCRs) specific for tumor-associated antigens is another promising approach for cancer immunotherapy. NY-ESO-1 is expressed in 10 to 50% of metastatic melanomas, lung, breast, prostate, thyroid and ovarian cancers as well as between 70 and 80% of synovial cell sarcomas. Interim results from clinical studies of NY-ESO-1 specific TCR engineered T-cells suggest generally  good tolerance with initial efficacy.

The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies and proteins targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1). In addition, the report lists company- and institution-specific R&D pipelines of NY-ESO-1-Targeted Immunotherapies. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Table of Contents:

1)        NY-ESO-1-Targeted Immunotherapy

  • NY-ESO-1 Selective Cancer Vaccines
  • NY-ESO-1 Specific, Multi-Target Cancer Vaccines
  • NY-ESO-1 Selective Adoptive Cell Therapy
  • NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
  • NY-ESO-1 Selective Recombinant Antibodies & Proteins

2)        Corporate & Institutional NY-ESO-1 Immunotherapy R&D Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top